BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12411298)

  • 1. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
    Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
    Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
    Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
    Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
    Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
    Wang L; Zhu K; Zha X; Chen S; Yang L; Chen S; Li Y
    J Hematol Oncol; 2010 Apr; 3():14. PubMed ID: 20377918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Feldman E; Najfeld V; Schuster M; Roboz G; Chadburn A; Silver RT
    Exp Hematol; 2003 Aug; 31(8):702-7. PubMed ID: 12901975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Goldman J
    Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G; Cortes JE
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.
    Loriaux M; Deininger M
    Leuk Lymphoma; 2004 Nov; 45(11):2197-203. PubMed ID: 15512807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.